Sugimoto Mayumi, Kamemura Norio, Nagao Mizuho, Irahara Makoto, Kagami Shoji, Fujisawa Takao, Kido Hiroshi
Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Division of Enzyme Chemistry, Institute for Enzyme Research, Tokushima University, Tokushima, Japan.
Pediatr Allergy Immunol. 2016 May;27(3):276-82. doi: 10.1111/pai.12535. Epub 2016 Feb 5.
Oral immunotherapy (OIT) induces desensitization and/or tolerance in patients with persistent food allergy, but the biomarkers of clinical outcomes remain obscure. Although OIT-induced changes in serum allergen-specific IgE and IgG4 levels have been investigated, the response of other allergen-specific IgG subclasses and IgA during OIT remains obscure.
A pilot study was conducted to investigate egg OIT-induced changes in allergen-specific IgE, IgG subclasses, and IgA levels and search for possible prediction biomarkers of desensitization. We measured serum levels of egg white-, ovomucoid-, and ovalbumin-specific IgE, IgA, and IgG subclasses by high-sensitivity allergen microarray in 26 children with egg allergy who received rush OIT.
Allergen-specific IgE gradually decreased while IgG4 increased during 12-month OIT. Serum levels of IgG1, IgG3, and IgA increased significantly after the rush phase, then decreased during the maintenance phase. IgG2 levels changed in a manner similar to that of IgG4. In particular, significantly high fold increases in egg white-specific IgG1, relative to baseline, after the rush phase and high IgA levels before OIT were observed in responders, compared with low-responders to OIT. Patients who could not keep desensitization showed relatively small changes in all immunoglobulin levels during OIT.
The response to OIT was associated with significant increases in serum allergen-specific IgG1 levels after rush phase and high baseline IgA levels, compared with small changes in immunoglobulin response in low-responders. The characteristic IgG1 changes and IgA levels in the responders could be potentially useful biomarkers for the prediction of positive clinical response to OIT.
口服免疫疗法(OIT)可诱导持续性食物过敏患者产生脱敏和/或耐受,但临床结局的生物标志物仍不明确。尽管已对OIT诱导的血清过敏原特异性IgE和IgG4水平变化进行了研究,但OIT期间其他过敏原特异性IgG亚类和IgA的反应仍不明确。
进行了一项初步研究,以调查鸡蛋OIT诱导的过敏原特异性IgE、IgG亚类和IgA水平变化,并寻找可能的脱敏预测生物标志物。我们通过高敏过敏原微阵列测量了26名接受速发型OIT的鸡蛋过敏儿童血清中蛋清、卵类黏蛋白和卵白蛋白特异性IgE、IgA和IgG亚类的水平。
在12个月的OIT期间,过敏原特异性IgE逐渐降低,而IgG4升高。速发期后,IgG1、IgG3和IgA的血清水平显著升高,然后在维持期降低。IgG2水平的变化方式与IgG4相似。特别是,与OIT低反应者相比,反应者在速发期后相对于基线的蛋清特异性IgG1显著高倍数增加,且OIT前IgA水平较高。无法维持脱敏的患者在OIT期间所有免疫球蛋白水平的变化相对较小。
与低反应者免疫球蛋白反应的微小变化相比,OIT的反应与速发期后血清过敏原特异性IgG1水平的显著升高和高基线IgA水平相关。反应者中特征性的IgG1变化和IgA水平可能是预测OIT临床阳性反应的潜在有用生物标志物。